Recombinant ParvoVirus B19 VP2 Protein

• Cat.No.: VP2-638P
• Product Overview: Recombinant ParvoVirus B19 VP2 Protein was expressed in HEK 293 cells.

Specification

• Species: ParvoVirus B19
• Source: HEK293
• Tag: Non
• Description: Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and whilst they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.
• Form: 20m m Tris-HCl pH 7.9, 10mM NaCl, less than 0.1% PEG-8000
• Purity: >95% pure by SDS-PAGE
• Storage: Store at 4 centigrade for short term, or frozen at -20 centigrade to -80 centigrade for long term.
• Concentration: 1.33mg/ml

Gene Information

• Gene Name: VP2 major capsid protein [ Human parvovirus B19 ]
• Official Symbol: VP2
• Synonyms: VP2; major capsid protein; capsid protein 2
• Gene ID: 11293627
• Protein Refseq: YP_004928148.1
• UniProt ID: Q76T28